The signature has been developed on fresh frozen (FF) breast tumors that were categorized as either BRCA1-like or non-BRCA1-like using a DNA copy number MLPA-based classifier [16], and endeavors to predict BRCA1-like tumors with a high sensitivity/specificity rate. Here, BRCA1 is linked to breast neoplasm.